8-K: Aimei Health Extends Business Combination Deadline

Aimei Health Technology Co., Ltd. secures a one-month extension for its business combination deadline, funded by a $150,000 promissory note.

Summary

• Aimei Health Technology Co., Ltd. (the "Company") has extended the period to consummate its initial business combination by one month, from October 6, 2025, to November 6, 2025.
• This is the tenth of up to 12 permitted extensions under the Company's Amended and Restated Articles of Association.
• An aggregate of $150,000 (the "Extension Payment") was deposited into the Company's trust account for public shareholders to facilitate this extension.
• The Company issued an unsecured promissory note in the total principal amount of $150,000 (the "Promissory Note") to Aimei Health Ltd (the "Sponsor") and United Hydrogen Group Inc. ("United Hydrogen").
• Each payee, Aimei Health Ltd and United Hydrogen Group Inc., contributed $75,000 to fund the Extension Payment.
• The Promissory Note does not bear interest and its principal becomes due and payable upon the consummation of a business combination with United Hydrogen.
• The Payees have the right, but not the obligation, to convert the Promissory Note, in whole or in part, into private units of the Company at a price of $10.00 per unit, immediately prior to the business combination.
• Each private unit consists of one ordinary share and one right to receive one-fifth (1/5) of one ordinary share.

Sentiment

Score: 5

Explanation: The extension prevents immediate liquidation, which is positive, but it also highlights continued delays and reliance on related-party funding, indicating ongoing challenges in completing the business combination.

Positives

• The extension provides an additional month for the Company to complete its initial business combination, preventing immediate liquidation.
• The funding for the extension was secured through a promissory note, indicating continued support from the Sponsor and the potential target, United Hydrogen Group Inc.

Negatives

• This marks the tenth extension, suggesting ongoing challenges or delays in consummating a business combination within the original timeframe.
• The Company is incurring additional financial obligations ($150,000 promissory note) to fund these extensions, which could lead to further dilution if converted to equity.

Risks

• Failure to consummate a business combination by the new termination date of November 6, 2025, could lead to the Company's liquidation.
• Reliance on related-party funding (Sponsor and United Hydrogen) for extensions may indicate difficulty in securing external financing or completing the deal.
• Potential dilution for existing shareholders if the promissory note is converted into private units at $10.00 per unit.
• The unsecured nature of the promissory note means payees are general creditors if the business combination does not occur and the note is not converted.

Future Outlook

The Company's immediate future outlook is focused on consummating a business combination with United Hydrogen Group Inc. by the newly extended deadline of November 6, 2025.

Management Comments

• Junheng Xie, Chief Executive Officer and Director, signed the report on behalf of Aimei Health Technology Co., Ltd.

Industry Context

This extension is common for Special Purpose Acquisition Companies (SPACs) that face challenges in identifying or closing a suitable business combination within their initial timeframe. Multiple extensions, often funded by sponsors or target companies, are a recurring theme in the SPAC market, reflecting the complexities of de-SPAC transactions.

Comparison to Industry Standards

• The need for multiple extensions (tenth of twelve) is not uncommon in the SPAC industry, where many vehicles struggle to complete a de-SPAC transaction within their initial timelines. For example, other SPACs like Gores Holdings VIII or Churchill Capital Corp IV also pursued multiple extensions to finalize their deals.
• The funding mechanism via a promissory note from the sponsor and the target company is a standard practice for SPACs seeking to extend their deadlines, as seen with numerous other SPACs that have utilized similar arrangements to maintain their trust accounts and avoid liquidation.
• The conversion option for the promissory note into private units at a fixed price ($10.00 per unit) is a typical incentive for the funding parties, aligning with common terms observed in SPAC extension financings.

Corporate Governance

Related Party Transactions

• The Company issued an unsecured promissory note for $150,000 to Aimei Health Ltd (the Sponsor) and United Hydrogen Group Inc. (the proposed business combination target), with each contributing $75,000.

Stakeholder Impact

• Shareholders: Face continued uncertainty regarding the business combination, potential dilution if the promissory note converts, but avoid immediate liquidation.
• Sponsor (Aimei Health Ltd): Provides additional funding, maintaining its interest in the SPAC and the potential business combination.
• Target Company (United Hydrogen Group Inc.): Contributes to the extension, indicating continued commitment to the proposed business combination.

Next Steps

• Consummate the initial business combination with United Hydrogen Group Inc. by November 6, 2025.

Key Dates

Recommendation

The extension provides additional time for the company to complete its business combination, preventing immediate liquidation. However, the need for a tenth extension and reliance on related-party financing for this extension suggest persistent challenges. Investors are likely holding for the outcome of the proposed business combination with United Hydrogen Group Inc.

Keywords

SPAC, business combination, extension, promissory note, Aimei Health Technology, United Hydrogen Group, Nasdaq, AFJK